Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients. (2021)

First Author: Marwick JA
Attributed to:  MICA: A new paradigm for testing pathway tractability in lung disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/24725552211019405

PubMed Identifier: 34078171

Publication URI: http://europepmc.org/abstract/MED/34078171

Type: Journal Article/Review

Volume: 26

Parent Publication: SLAS discovery : advancing life sciences R & D

Issue: 9

ISSN: 2472-5552